IP Library › Granted Patent US 9,320,803
Granted Patent B2
US 9,320,803 · App. 14/001,387 · Granted Apr 26, 2016

Bisphosphonate-prodrugs

Inventors: Felix Kratz (Ehrenkirchen, DE); Katrin Hochdoerffer (Kressbonn, DE)
Assignee: KTB Tumorforschungsgesellschaft MBH
A61K47/48084A61K31/35A61K31/40A61K31/704A61K47/48338C07D405/00C07H15/252C07K5/06026C07K5/06052C07K5/06139A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,320,803
App. No.
14/001,387
Granted
Apr 26, 2016
Kind
B2
Abstract

The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.

Claims (1)

1. A prodrug selected from the group consisting of:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2019
From: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
To: VERGELL MEDICAL S.A.
Reel/Frame 048503/0308 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2013
From: KRATZ, FELIX; HOCHDOERFFER, KATRIN
To: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
Reel/Frame 031555/0313 →
Priority Claims (1)
EP 11001551 · Feb 24, 2011 · regional
Continuity (1)
Related Publication 20140051623A1 · Feb 20, 2014